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A B S T R A C T
The aim of the study was to investigate the antiproliferative, antiangiogenic and apoptotic effect of photochemo-
therapy (PUVA) in psoriatic patients, and to compare it with a control group of psoriatics treated with local corticosteroid
therapy. The study included 60 psoriasis patients, 30 of them allocated to PUVA therapy and local corticosteroid each.
Immunohistochemical methods of staining with Ki-67, F-8 and bcl-2 antibodies were used to determine proliferative
keratinocyte count, to visualize the number of blood vessels in the dermis, and to determine the number of cells exhibiting
expression of the antiapoptotic oncoprotein bcl-2, respectively. In all study patients, the values of Ki-67, F-8, bcl-2 and
PUVA score were recorded pre- and at six weeks post-therapeutically. Study results showed a statistically significant de-
crease in the epidermal proliferative keratinocyte count and dermal number of blood vessels after both therapeutic mo-
dalities (p<0.001 both). The value of bcl-2 showed a statistically significant increase in the group of patients treated with
PUVA therapy (p=0.001) and an increase in the control group, demonstrating enhanced keratinocyte apoptosis after
treatment. Accordingly, study results demonstrated the antiproliferative, antiangiogenic and apoptotic effect of both PUVA
and local corticosteroids. These very mechanisms appear to play a key role in the action of most antipsoriatic therapies.
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Introduction
According to current concepts, psoriasis is an autoim-
mune, T-lymphocyte induced, cytokine and chemokine
mediated disease1. Psoriasis is characterized by hyper-
proliferation and resistance of keratinocytes to apop-
tosis2. Vascular lesions in psoriasis include vascular dila-
tation and tortuosity in papillary dermis, and angiogenesis3.
Angiogenesis is a key component of the psoriatic process
promulgated by a variety of cytokines and angiogenic
growth factors. These lesions are highly relevant, since
increased intralesional microcirculation may precipitate
the passage of T-lymphocytes to the skin, thus endothe-
lial venules playing an important role in the genesis of
psoriasis4. Apoptosis is the general name for physiologic
cell death caused by activation of an energy-dependent
suicide program5,6. In psoriasis, an increased apoptosis
has been observed in the differentiated layers. It has
been considered as a counteracting factor of cell overpro-
duction by the germinative compartment7,8. The exact
cause of psoriasis remains unknown, therefore the treat-
ment is symptomatic. PUVA (psoralen + ultraviolet A)
has for years been used in the treatment of psoriasis
vulgaris involving more than 30% of the skin area, but its
mechanism of action has not yet been fully elucidated.
The aim of the study was to investigate the antipro-
liferative, antiangiogenic and apoptotic effect of PUVA in
psoriasis patients by immunohistochemical analysis us-
ing Ki-67, F-8 and bcl-2 antibodies, and to compare it
with the action of topical corticosteroids as a control
group9–12.
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Materials and Methods
The study was carried out at University Department
of Dermatology and Venereology, Zagreb University Hos-
pital Center in Zagreb. Sixty patients diagnosed with sta-
ble chronic plaque psoriasis gave their informed consent
in writing and were randomized into two treatment
groups. Experimental group included 30 patients with
chronic plaque psoriasis involving more than 30% of the
skin area, with indications for PUVA therapy. Control
group included 30 psoriasis patients with indications for
local corticosteroid therapy. In all patients, psoriasis skin
involvement was evaluated according to the Psoriasis
Area and Severity Index (PASI) score13 before and after
treatment. All patients had discontinued topical anti-
psoriatic medication for at least 4 weeks and any sys-
temic antipsoriatic medication for at least 8 weeks prior
to pretrial assessment. Before patient inclusion in PUVA
group, complete blood count, renal and hepatic function
tests, and ophthalmologic examination were performed
in each patient, and those having normal results were
enrolled in the study. PUVA therapy was administered
according to the European protocol four times weekly for
five weeks with 20 exposures per patient in total14. Ac-
cording to the protocol, experimental group patients
were administered the oral photosensitizer 8-methoxy-
psoralen in a dosage of 0.6 mg/kg, followed by ultraviolet
A ray (UVA) irradiation after two hours. Control group
patients applied a thin layer of corticosteroid ointment
(betamethasone-diproprionate) exclusively onto psoriat-
ic lesions twice daily. Biopsy specimens were obtained
from lesional skin before treatment and from the same
lesion after the treatment in both patient groups. All bi-
opsy specimens were analyzed immunohistochemically
(cell immunophenotyping). Paraffin block 3-µm sections
were used on immunohistochemistry staining. Sections
were stained by the standard immunoperoxidase avidin-
-biotin method on an automated staining device (Teh-
Mate, Dako, Glostrup, Denmark) using primary antibod-
ies (anti-Ki-67, anti-F-8, and anti-bcl-2) from the same
manufacturer. The specimens were deparaffinized, buf-
fer treated in a microwave oven (EDTA, pH 9.0, 15 min)
to enhance antigen reaction, and stained in an auto-
mated device using capillary activity. Antibodies were
used in 1:100 dilution. The reaction was visualized by
use of diaminobenzidine (DAB, Dako, Glostrup, Den-
mark). Stained preparations were analyzed under light
microscope. Proliferative index of the epidermis cells was
expressed as percentage of positive anti-Ki-67 antibody
stained cells. Positive reaction is nuclear cell staining.
Anti-F-8 antibody staining revealed vascular endothelial
cells in the skin specimens. Thus visualized blood vessels
were counted per mm2 specimen using the microscope
mesh determining the given area. In this way, the abso-
lute number of dermis blood vessels was shown in the re-
spective skin specimens. Positive reaction on epidermal
keratinocytes as well as membrane and cytoplasmic sta-
ining were visualized by anti-bcl-2 antibody staining.
Positive cells were counted under a light microscope and
expressed as number of positive cells per 100 counted
cells (%). The Ki-67, F-8, bcl-2 and PASI score evaluation
was performed at baseline and was repeated at 6 weeks
of either therapy.
Statistical data analysis was done by description of all
groups and all characteristics. The significance of thera-
peutic effect, i.e. differences between pretherapeutic and
post-therapeutic condition, was determined by t-test for
dependent samples (paired samples t-test).
Results
According to sex distribution, there were 53.3% of
male and 46.7% of female patients in both experimental
and control group. The parameters of proliferative, an-
giogenic and antiapoptotic activity showed a statistically
significant post-therapeutic decrease in both patient groups
treated with PUVA therapy and local corticosteroid ther-
apy (Table 1). Comparison of changes in the parameters
of antiproliferative, antiangiogenic and apoptotic effect
between the groups of patients treated with PUVA ther-
apy (Fig. 1) and corticosteroids (Fig. 2) showed the two
treatments to have similar effects on Ki-67. The mean
pretherapeutic and post-therapeutic value of Ki-67 was
50.0 and 32.3 in the experimental group versus 58.4 and
34.1 in the control group (Tables 1 and 2). A similar pat-
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TABLE 1
PARAMETERS OF ANTIPROLIFERATIVE, ANTIANGIOGENIC AND APOPTOTIC EFFECT OF PUVA THERAPY AND RESULTS OF T-TEST
FOR DEPENDENT SAMPLES
Variables Na X s t df p
Ki-67 Before therapy 30 50.0 25.08 4.74 29 <0.001
After therapy 30 32.3 21.81
F-8 Before therapy 30 25.0 12.00 5.70 29 <0.001
After therapy 30 14.7 9.24
bcl-2 Before therapy 30 16.0 13.40 –3.83 29 0.001
After therapy 30 24.0 16.88
PASI score Before therapy 30 44.6 8.72 15.46 29 <0.001
After therapy 30 13.4 6.99
aNumber of cases
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tern was also observed in the changes recorded in F-8 and
bcl-2 (Tables 1 and 2, Figs. 1 and 2). Differences between
the pretherapeutic and post-therapeutic mean PASI sco-
re in the two patient groups are depicted in Figs. 1 and 2.
In the PUVA therapy group, the mean pretherapeutic
and post-therapeutic PASI score was 44.6 (SD=8.72) and
13.4 (SD=6.99), respectively (Table 1). In the control
group, the respective PASI score values were 12.8 (SD=
2.92) and 6.5 (SD=5.01) (Table 2, Figs. 1 and 2).
Discussion
Topical treatment of psoriasis includes corticosteroids,
vitamin D analogs, dithranol (anthralin) and retinoids.
Systemic therapy includes photochemotherapy (PUVA),
retinoids, methotrexate, immunosuppressants and biolo-
gicals. PUVA is the most widely used systemic antipso-
riatic therapy and its efficacy has been largely documented.
PUVA has an antiproliferative and immunosuppressive
action15. In PUVA treated psoriatic skin, the numbers of
epidermal and dermal CD3+T-lymphocytes as well as of
CD4, CD8 and IL-2 receptor+subsets are strongly re-
duced16. Peripheral blood mononuclear cells obtained
from psoriatic patients before and upon completion of
PUVA therapy showed inhibition of the production and
release of interleukin-1b (IL-1b), interleukin 6 (IL-6),
interleukin 8 (IL-8) and tumor necrosis factor-a (TNF-a)17.
The number of Langerhans cells is reduced after PUVA,
although remission of psoriasis seems to be independent
of the magnitude of this effect18,19. PUVA has no measur-
able effect on complement components and immunoglob-
ulin levels in psoriatic patients20. In spite of all these
facts and its longstanding use, the mechanism of action
of PUVA therapy on psoriatic skin has not yet been fully
elucidated21. Considering the above mentioned new con-
cepts on the pathogenesis of psoriasis, we investigated
the antiproliferative, antiangiogenic and apoptotic action
of PUVA, and compared it to local corticosteroid therapy
and clinical picture of the disease. PUVA can reverse the
pathologically altered pattern of keratinocyte differenti-
ation markers and reduce the number of proliferating
epidermal cells21. The Ki-67 protein is essential for cell
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Fig. 1. Changes in the parameters of antiproliferative, antian-
giogenic and apoptotic action following PUVA therapy (n=30).






















Fig. 2. Changes in the parameters of antiproliferative, antian-
giogenic and apoptotic action following local corticosteroid therapy
(n=30).
TABLE 2
PARAMETERS OF ANTIPROLIFERATIVE, ANTIANGIOGENIC AND APOPTOTIC EFFECT OF CORTICOSTEROID
THERAPY AND RESULTS OF T-TEST FOR DEPENDENT SAMPLES
Variables Na X s t df p
Ki-67 Before therapy 30 58.4 15.41 6.12 29 <0.001
After therapy 30 34.1 17.65
F-8 Before therapy 30 30.1 16.59 5.25 29 <0.001
After therapy 30 17.7 13.20
bcl-2 Before therapy 30 14.0 12.40 –2.14 29 0.041
After therapy 30 21.1 17.09
PASI zbroj Before therapy 30 12.8 2.92 6.58 29 <0.001
After therapy 30 6.5 5.01
aNumber of cases
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proliferation and has been widely used as a proliferation
marker9,10. In psoriasis, the expression of proliferative
proteins is increased9,21,22. In the present study, the pro-
liferating keratinocyte count was determined by use of
Ki-67 antibody before and after PUVA therapy (Fig. 3)
and local corticosteroid therapy. The levels of Ki-67 ex-
pression decreased after both treatments. These findings
confirmed the expected antiproliferative effect of PUVA
and steroid therapy in psoriatic lesions, which is consistent
with literature data23,24. To our knowledge, there are no lit-
erature reports on the assessment of the proliferative effect
of PUVA therapy by this immunohistochemistry method
using the proliferation factor Ki-67. Hannuksela-Svahn et
al. investigated p53 expression before and after PUVA
therapy, with immunohistochemical determination of pro-
liferation by use of Ki-67 in psoriatic and non-lesional skin
before and after PUVA therapy; their results were consis-
tent with those reported herewith21.
Although psoriasis is primarily a lymphocyte driven
disease, the prominence of dermal microvascular expan-
sion in lesional skin suggests that psoriasis is angiogenesis
dependent25. As early as 1972, Folkman identified vaso-
proliferation as a suitable target for the development of
anti-psoriatic drugs26. His concepts proved correct, since
currently there is evidence for the antiangiogenic effect
of various antipsoriatic treatments in use, while research
into new antipsoriatics is just under way27–29.
In the present study, we investigated the number of
blood vessels in the psoriatic lesions dermis before and
after PUVA (Fig. 4) and local corticosteroid therapy. En-
dothelial cells were stained using monoclonal anti-F-8
antibody. The value of F-8 showed a statistically signifi-
cant decrease (p<0.01) in both patient groups, i.e. both
therapies led to a decrease in the number of blood vessels
within the treated plaques.
Results of the present study demonstrated the anti-
angiogenic action of both PUVA and local corticosteroid
therapy, confirming the concept of angiogenic activity as
one of the key mechanisms in the management of pso-
riasis3,10.
Braverman and Sibley studied the relation of vascular
changes to epidermal changes in psoriatic skin undergo-
ing PUVA. The degree of epidermal proliferation was
quantified by autoradiography, while the state of dermal
capillaries was monitored ultrastructurally by electron
microscopy. As a result, they suggest that the response to
PUVA therapy is mediated via microvasculature rather
than any antiproliferative effect on basal keratinocytes30.
They also conducted a study in psoriatic patients treated
by Goeckerman’s method, with similar results30. In Cro-
atia, the antiangiogenic effect of naphthalene was dem-
onstrated by Vr`ogi} et al.31, by use of immunohisto-
chemistry methods of vascular staining, also employed in
the present study.
Determination of the number of blood vessels by
immunohistochemical labeling of endothelium using F-8
antibody as well as determination of vascular endothelial
growth factor (VEGF) in blood32,33 can be used as a reli-
able indicator of the clinical course of the disease and
therapeutic effect by acting upon neoangiogenesis.
Keratinocyte apoptosis in psoriasis remains an inade-
quately investigated and poorly elucidated process in
which many genes and their products are involved. Among
them, the bcl-2 gene plays a major role. The expression of
bcl-2 is restricted to cell populations with a long lifespan
or proliferative activity, and it prevents apoptosis6. In
normal skin, the expression of bcl-2 gene is present in the
basal layers of the epidermis34–36. In psoriatic skin, a de-
creased expression of bcl-2 relative to normal skin has
been demonstrated37–39.
In the present study, the apoptotic effect of PUVA and
corticosteroid therapy on keratinocytes was investigated
by use of bcl-2 antibodies. A statistically significant in-
crease of bcl-2 value was recorded in both PUVA treated
group (Fig. 5) and control group of patients. These re-
sults suggested that in addition to lymphocytes40,41, PUVA
therapy also induced apoptosis in keratinocytes, and that
the psoriasis regression following PUVA therapy was
also related to the enhanced keratinocyte apoptosis in
the basal layer of the epidermis. In our study, bcl-2 ex-
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Fig. 3. A psoriatic skin specimen before and after PUVA therapy;
anti-Ki-67 antibody staining (background staining with hemalaun,
x200).
Fig. 4. Psoriatic skin before and after PUVA therapy; anti-F-8 an-
tibody staining (background staining with hemalaun, x200).
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pression was observed in keratinocytes obtained from all
over the epidermis, without isolation of particular layers.
Basal layer keratinocytes showed highest bcl-2 expres-
sion, whereas most terminally differentiated keratino-
cytes from the upper layers of the epidermis showed no
cytochemical staining at all, i.e. no bcl-2 expression. Only
melanocytes and cells of the basal layer of the epidermis,
i.e. dividing cells, show bcl-2 gene expression34,35. Our re-
sults are consistent with the report by Laporte et al., who
found the apoptosis to be considerably reduced in the
basal layer of the epidermis in psoriasis, while being
greatly enhanced at the site of regressive psoriatic plaque
following PUVA therapy. They concluded that apoptosis
was the key factor for post-therapeutic psoriasis regres-
sion, and used apoptotic index to calculate the time
needed for psoriatic plaque regression after PUVA ther-
apy, which was one to two months42. Yamamoto and
Nishioka found increased bcl-2 expression in the basal
layer of the epidermis in psoriatic skin following an-
thralin therapy43. Heenen et al. showed that, in addition
to immunosuppressive action, methotrexate also influ-
enced keratinocyte apoptosis44. Adisen et al. report on
the same effects by use of calcipotriol and local steroids45.
Accordingly, these literature reports and our own results
suggest that the induction of keratinocyte apoptosis in
the basal layer of the epidermis is one of the mechanisms
of action exerted by antipsoriatic therapies currently in
use. Our study confirmed the well-known efficacy of
PUVA therapy and local corticosteroid therapy by com-
parison of pretherapeutic and post-therapeutic PASI sco-
re4,46–48. The statistically significant difference (p<0.001)
in the PASI score between the experimental (PUVA tre-
ated) and control group of patients was not accidental,
but resulted from the choice of therapeutic modality ac-
cording to the dissemination of psoriatic lesions in par-
ticular patients (Table 1, Figure 1).
Conclusion
Study results demonstrated that both PUVA therapy
and local corticosteroid therapy decreased the Ki-67 and
F-8 expression, and increased bcl-2 expression. Thus,
PUVA therapy and local corticosteroid therapy were con-
firmed to efficently act on the main pathogenetic mecha-
nisms of psoriasis, i.e. to exert antiproliferative, anti-
angiogenic and apoptotic action. These very mechanisms
appear to play a key role in therapeutic effects of most
antipsoriatic treatments. PUVA resulted in excellent im-
provement of the clinical picture in psoriasis patients. In
spite of the ever growing fear from UV exposure, even for
therapeutic purpose, we believe that because of its effi-
cacy PUVA will for a while remain the first choice ther-
apy in the management of psoriasis vulgaris involving
more than 30% of the skin area in patients free from con-
traindications for this therapy.
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ANTIPROLIFERACIJSKI, ANTIANGIOGENI I APOPTOTI^NI U^INAK
FOTOKEMOTERAPIJE (PUVA) U BOLESNIKA S PSORIJAZOM
S A @ E T A K
Cilj ovoga rada bio je istra`iti antiproliferacijsko, antiangiogeno i apoptoti~no djelovanje fotokemoterapije (PUVA) i
usporediti ga s kontrolnom skupinom bolesnika lije~enih lokalnim steroidom. U istra`ivanje je bilo uklju~eno 60 bo-
lesnika, od kojih je 30 lije~eno PUVA terapijom, a 30 lokalnim steroidom. U istra`ivanju su primijenjene imunohis-
tokemijske metode bojenja protutijelima Ki-67, F-8 i bcl-2. Pomo}u anti protutijela Ki-67 mjeren je broj keratinocita u
proliferaciji, pomo}u anti protutijela F-8 prikazan je broj krvnih `ila u dermisu, a pomo}u protutijela bcl-2 prikazan je
broj stanica koje pokazuju ekspresiju antiapoptoti~kog onkoproteina bcl-2. Kod svih bolesnika je prije terapije i nakon
{est tjedana odre|ena vrijednost Ki-67, F-8 i bcl-2 te PUVA zbroj. Rezultati istra`ivanja pokazali su statisti~ki zna~ajne
razlike u smanjenju broju keratinocita u proliferaciji u epidermisu (p<0,001) i smanjenju broja krvnih `ila u dermisu
(p<0,001) prije i nakon obiju vrsta lije~enja. Vrijednost bcl-2 statisti~ki je zna~ajno porasla u bolesnika lije~enih PUVA
terapijom (p=0,001), kao i u kontrolnoj skupini, tj. dokazana je pove}ana apoptoza keratinocita nakon lije~enja. Re-
zultati istra`ivanja dokazali su antiproliferacijsko, antiangiogeno i apoptoti~no djelovanje PUVA i lokalne steroidne
terapije. ^ini se kako su upravo istra`ivani mehanizmi djelovanja klju~ni u djelovanju ve}ine antipsorijati~nih terapija.
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